Objective To determine whether seropositivity in rheumatoid arthritis patients treated with
adalimumab (ADL) is associated with the presence of anti-adalimumab (anti-ADL) …

Objetivo Determinar si la seropositividad en pacientes con artritis reumatoide tratados con
adalimumab (ADL), se asocia a la presencia de anticuerpos anti-adalimumab (anti-ADL) …

AbstractBackground: The Interleukin (IL)-37 is a member of IL-1 cytokines and reported to
down-regulate inflammation as a natural suppressor of innate immune responses. We …

Rheumatoid arthritis (RA) is a chronic, pathological condition caused by systemic
inflammation. Rampant activation and infiltration of immune cells into the joints often leads to …

The possibility of tailoring treatment on specific characteristics of patients–ie personalized
medicine–has received attention in the field of rheumatic diseases since biological DMARDs …

[78] Podstawy immunologii dla reumatologów warianty łańcuchów lekkich: κ (kappa) i λ
(lambda). W obrębie tej samej klasy nieznaczne różnice w budowie łańcuchów ciężkich …

Background In rheumatoid arthritis (RA) treatment, bDMARDs and tsDMARDs (BIO) perform
tremendous disease activity control, however, its effectiveness is uncertain and unstable …

Background Recent randomized trials in rheumatoid arthritis (RA) using low to medium dose
of corticosteroid showed that bone mineral density (BMD) loss over 2 years was not …

Background Long since it have been suggested that seronegative rheumatoid arthritis (RA)
represents a clinical entity quite distinct from that of seropositive RA. However, analytical …

Background: Seronegative Rheumatoid Arthritis (RA) is a disorder associated with
considerable diagnostic, prognostic and therapeutic uncertainty for many clinicians …